What are the challenges of the Promotion of Medication-Assisted Treatment (MAT) program?


According to the “Healthcare Payer Strategies to Reduce the Harms of Opioids” white paper, “Even when available, the use of MAT may present challenges. Payers may place limits on MAT dosages prescribed or other medication limits, require prior authorization to initiate treatment and provide insufficient coverage for concurrent counseling and step therapy. Fear of diversion and low patient utilization may also lead many providers to avoid prescribing MAT or prescribe it at insufficient dosages.”


CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.